Clinical trial results support adalimumab treatment for painful skin condition

The results of two phase 3 clinical trials that led to FDA approval of adalimumab for treatment of the chronic inflammatory skin disease hidradenitis suppurtiva are now being published. An inhibitor of the inflammatory protein tumor necrosis factor, adalimumab is the first such medication approved to treat the painful skin disorder.